Investigating how a specific protein helps adeno-associated virus vectors deliver genes effectively

Studies of the KIAA0319L-mediated productive transduction pathways of rAAV vectors

NIH-funded research University of Kansas Medical Center · NIH-10997358

This study is looking at how a special virus used in gene therapy gets into cells and delivers helpful genes, focusing on a protein that helps this process, with the goal of making gene therapies work better for people with different health conditions.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Kansas Medical Center NIH-funded
Lab location1 site (Kansas City, United States)
Project IDNIH-10997358 on NIH RePORTER

What this research studies

This research focuses on understanding the mechanisms by which recombinant adeno-associated virus (rAAV) vectors, which are used in gene therapy, enter cells and deliver genetic material. The study specifically examines the role of a protein called KIAA0319L, which has been identified as a receptor that facilitates the binding and entry of these vectors into cells. By exploring the interactions between rAAV vectors and KIAA0319L, the research aims to overcome existing barriers to effective gene delivery, potentially improving the outcomes of gene therapies for various conditions.

Who could benefit from this research

Good fit: Ideal candidates for this research include patients with genetic conditions that could be treated with rAAV-based gene therapies, such as inherited blindness or spinal muscular atrophy.

Not a fit: Patients with conditions that are not targeted by rAAV-based therapies may not receive any benefit from this research.

Why it matters

Potential benefit: If successful, this research could enhance the effectiveness of gene therapies, leading to better treatment options for patients with genetic disorders.

How similar studies have performed: Previous research has shown promising results with rAAV vectors in gene therapy, indicating that this approach has potential for success.

Where this research is happening

Kansas City, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Aran-Duchenne disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.